Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Purchases 20,000 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon bought 20,000 shares of the stock in a transaction dated Monday, November 9th. The shares were bought at an average price of $8.24 per share, for a total transaction of $164,800.00. Following the completion of the acquisition, the director owned 5,234,578 shares in the company, valued at approximately $43,132,922.72. The trade was a 0.38% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Electra Therapeutics Price Performance

ETRA stock opened at $7.99 on Wednesday. Electra Therapeutics, Inc. has a 1 year low of $6.86 and a 1 year high of $15.50.

Electra Therapeutics News Roundup

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, through OrbiMed Advisors, reported purchases totaling 92,116 shares across November 6, 9 and 10, at prices ranging from $7.85 to $8.45 per share. Repeated buying by a director may signal confidence in the company, although it does not guarantee future performance. SEC ownership filing
• Neutral Sentiment: A report said short interest stood at zero shares as of November 10, with zero days to cover. That figure does not indicate meaningful reported short positioning, but it conflicts with the report’s description of a “significant increase,” making the short-interest update difficult to interpret.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Zacks Research raised Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Wall Street Zen raised Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. JPMorgan Chase & Co. began coverage on Electra Therapeutics in a research note on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 target price for the company. Jefferies Financial Group began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.